STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Clinical trials for STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…
Matched conditions: STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
Can a weekly chemo schedule be gentler but just as effective for head and neck cancer?
Disease control TerminatedThis study compares two schedules of the chemotherapy drug cisplatin given alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see which schedule causes fewer side effe…
Matched conditions: STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 17, 2026 12:03 UTC
-
Immunotherapy before surgery shows promise for tough skin cancers
Disease control TerminatedThis study tests whether adding the immunotherapy drug cemiplimab to standard surgery (with or without radiation) helps people with advanced squamous cell skin cancer that can be surgically removed. About 420 adults with stage III or IV disease will be randomly assigned to receiv…
Matched conditions: STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC